secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001404644-24-000089
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene raises $200M in oversubscribed PIPE; funds into H2 2027
-----------------------------------------------------------------

- Gross proceeds of ~$200M from sale of 1.835M shares at $50/share and 2.165M pre-funded warrants at $49.999 each.
- Participating investors include RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, Commodore Capital, Samsara BioCapital.
- Proceeds expected to fund company into second half of 2027 and support NGN-401 registrational study and CMC scale-up.
- Closing expected Nov 5, 2024; post-transaction shares outstanding ~21.0M (assuming full warrant exercise).
- Company to host webcast Nov 11, 2024 to review Phase 1/2 interim data for NGN-401 Rett syndrome gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000089/0001404644-24-000089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464424000089/ngne-20241104.htm
  HTML page:      https://secwatch.observer/filing/0001404644-24-000089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer